title: Assessing health-state utility values in patients with metastatic colorectal cancer: a utility study in the United Kingdom and the Netherlands.
abstract: OBJECTIVE
  This study aimed to elicit EuroQol Quality of Life 5-Dimensions (EQ-5D) utility values from patients with second-line metastatic colorectal cancer (mCRC) pre- and post-progression.
  
  
  METHODS
  A cross-sectional study was conducted in five hospitals in the Netherlands and the UK. Patients with mCRC were eligible if prescribed a second or subsequent line of therapy or best supportive care (BSC), received prior oxaliplatin in first-line therapy, and had Eastern Cooperative Oncology Group (ECOG) performance status scores of 0-2 at second-line initiation. Patients completed the EuroQol Quality of Life 5-Dimensions 3-levels (EQ-5D-3L) questionnaire and were categorized as pre- or post-progression. Chart data including patient demographics, clinical history, prior/current treatments and serious adverse events (SAEs) were collected. Mean utilities were estimated; uni- and multivariate analyses were conducted.
  
  
  RESULTS
  Seventy-five patients were enrolled; 42 were pre-progression defined as second line or third line following an AE on second line and 33 were post-progression defined as third or subsequent therapy lines or BSC. Patient/disease characteristics and number of SAEs were similar between cohorts. Mean utility scores were 0.741 (SD = 0.230) and 0.731 (SD = 0.292) for pre- and post-progression cohorts, respectively. Compared to pre-progression, more patients reported increased anxiety/depression (36 vs. 12 %) and fewer problems with daily activities (64 vs. 38 %) post-progression. More patients pre-progression were on active treatment at enrolment (83 vs. 42 %) compared to post-progression.
  
  
  CONCLUSIONS
  This is the first real-world study to collect utilities for patients with second-line mCRC pre- and post-disease progression. Utility values were similar pre- and post-progression. To further explore the effect of radiological progression on utilities, longitudinal research is required that includes patients in palliative care centres.
authors: United BioSource Corporation, 185 Dorval Avenue, Suite 500, Dorval, QC, H9S 5J9, Canada, dara.stein@ubc.com.
authors: Dara
authors: D
authors: Stein
authors: F
authors: F
authors: Joulain
authors: S
authors: S
authors: Naoshy
authors: U
authors: U
authors: Iqbal
authors: N
authors: N
authors: Muszbek
authors: K A
authors: KA
authors: Payne
authors: D
authors: D
authors: Ferry
authors: S H
authors: SH
authors: Goey
mesh_terms: D000203:Activities of Daily Living; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001007:Anxiety / Q000209:etiology; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000523:psychology* / Q000556:secondary; D003430:Cross-Sectional Studies; D003863:Depression / Q000209:etiology; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D000077150:Oxaliplatin; D010146:Pain / Q000209:etiology; D010166:Palliative Care; D011788:Quality of Life; D011795:Surveys and Questionnaires; D006113:United Kingdom
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin